Zevra Therapeutics (ZVRA) EV to CFO (2021 - 2026)
Zevra Therapeutics' (ZVRA) EV to CFO stood at 11.78 in Q3 2026, down 37.5% from the prior quarter.
Powered by 
Analysis
Zevra Therapeutics (ZVRA) EV to CFO (2021 - 2026) Analysis & Trends
On a TTM basis, Zevra Therapeutics' EV to CFO came in at -4.05 as of Sep 30, 2026; for FY2021, it came in at 47.65.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Eli Lilly | 1,348.13 Bn | 1,321.74 Bn | 20.46 Bn |
| 2 | Johnson & Johnson | 675.90 Bn | 595.76 Bn | 17.30 Bn |
| 3 | AbbVie | 519.45 Bn | 487.50 Bn | 13.12 Bn |
| 4 | Merck | 364.95 Bn | 327.95 Bn | 13.19 Bn |
| 5 | Novartis Ag | 311.58 Bn | 285.16 Bn | - |
| 6 | Astrazeneca | 289.34 Bn | 262.94 Bn | 13.26 Bn |
| 7 | Amgen | 251.64 Bn | 203.30 Bn | 7.58 Bn |
| 8 | Gilead Sciences | 212.05 Bn | 187.07 Bn | 6.73 Bn |
| 9 | Pfizer | 167.35 Bn | 115.00 Bn | 12.56 Bn |
| 10 | Zevra Therapeutics | 708.52 Mn | -100.24 Mn | 36.01 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Sep 30, 2026 | 11.78 |
| Jun 30, 2026 | 18.84 |
| Mar 31, 2026 | 27.44 |
| Mar 31, 2022 | 25.84 |
| Dec 31, 2021 | 47.65 |
| Sep 30, 2021 | 51.58 |
| Jun 30, 2021 | 64.21 |
API Access
Zevra Therapeutics EV to CFO API
Pull this series into your own models, spreadsheets and apps with the Business Quant
Historical Metrics API. The request below matches the chart above — change the
frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.
https://data.businessquant.com/historic?slug=ev-to-cfo&ticker=ZVRA&period=max&api_key=YOUR_API_KEYimport requests
url = "https://data.businessquant.com/historic"
params = {"slug": "ev-to-cfo", "ticker": "ZVRA", "period": "max", "api_key": "YOUR_API_KEY"}
data = requests.get(url, params=params).json()const res = await fetch("https://data.businessquant.com/historic?slug=ev-to-cfo&ticker=ZVRA&period=max&api_key=YOUR_API_KEY");
const data = await res.json();